Teva Presents Latest Schizophrenia Portfolio Data

 

• UZEDY® (risperidone) demonstrates lower relapse rates and improved treatment adherence compared to oral alternatives.
• TEV-'749 (olanzapine) shows no incidence of PDSS in Phase 3 SOLARIS trials.
• Teva Pharmaceuticals strengthens its position in the schizophrenia treatment landscape with innovative long-acting injectables.

https://www.gurufocus.com/news/2899820/teva-presents-latest-schizophrenia-portfolio-data-including-realworld-outcomes-with-uzedy-risperidone-showing-lower-rates-of-and-longer-time-to-relapse-compared-to-oral-treatment-options-and-new-p